Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
1.2K Following 146.1K Followers
We’re breaking ground in Houston, TX — the latest manufacturing site as part of our $50+ billion investment in domestic production. Not only will this new facility create hundreds of jobs, but it will help us get our medicines to people faster.
#WeAreLilly#
Show more
What keeps us awake, alert and engaged each day?
See how orexin, a signal deep in the brain, may help influence everyday life:
#WorldNarcolepsyDay#
Obesity and type 2 diabetes rarely occur alone. That's why it's important to have treatment options that address different patient's needs. This is the thinking behind our work at the upcoming #EASD2026# conference in Milan, Italy. Read more about our approach:
Show more
Today, the FDA approved Lilly's new oral treatment for people with ESR1-mutated #BreastCancer#, which targets two key drivers of ER+ breast cancer. Learn more:
Show more
Millions of people live with diabetes and obesity, and the science keeps moving forward. This month, researchers and clinicians will gather in Milan for #EASD2026#. We'll be there, sharing new findings as we work together to advance cardiometabolic health:
Show more
New one-year data showed durable improvements in psoriasis, psoriatic arthritis and obesity:
When you live with type 2 diabetes, the conversation is usually about blood sugar. It should also be about your heart❤.
Read more:
Heart disease is the leading cause of death for people living with type 2 diabetes. Today the FDA approved a new use for one of our type 2 diabetes medicines, lowering the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events. Read more:
Show more
Lilly’s injectable weight management medicine was linked to lower healthcare costs over time compared to those not on treatment. Read more from this new study:
Show more
Protect your health: retatrutide is being studied in clinical trials and hasn’t been approved for sale to consumers. You don’t know what’s in black-market unapproved “reta.” Don’t take the risk. Learn more:
Show more
Helping more patients, growing our business, advancing our innovative pipeline, expanding for the future – our second quarter results continued to build momentum in a strong 2026. Read more:
Show more
A Breakthrough Therapy designation granted by the @FDA will help advance a potential treatment option that could be meaningful for previously treated patients with a certain form of advanced #pancreaticcancer#.
Learn more:
Show more
Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist.
Learn more:
Innovation is redefining what’s possible in retinal disease, and we’re working every day to advance progress in ophthalmology research to help people living with wet age-related macular degeneration.
Show more
Emerging research could offer a new approach to treatment-resistant depression. Read more on our agreement to acquire AtaiBeckley, a clinical-stage company developing innovative medicines for mental health conditions.
Show more
A new pathway for access to obesity treatment through Medicare begins July 1. Eligible Medicare Part D patients may be able to get certain medicines for weight management through Medicare GLP-1 Bridge.
Learn more and see the CMS Medicare GLP-1 Bridge Clinical Criteria:
Show more
In a late-breaking oral presentation, Lilly shared Phase 3 study results for one of our medicines as part of a time-limited regimen in chronic lymphocytic leukemia (#CLL#).
Learn more here:
Show more
In an oral presentation at #EHA2026#, initial clinical results will be shared from a Phase 1 study evaluating a first-in-class therapy in previously treated myelofibrosis.
Learn more here:
Show more
The @US_FDA has approved a new dosing option for Lilly’s moderate-to-severe atopic dermatitis (#eczema#) treatment. Learn more about what this may mean for patients:
Show more
That’s a wrap on #ADA2026#. It left us with important reminders about why science matters and who it’s for. #WeAreLilly#
